Disruption of Calmodulin and Huntington Protein Interactions as a Drug Target for Huntington's Disease

Track Code: 
09KU021L
Summary: 

KU researchers have developed a drug target for the treatment of Huntington's disease.

Overview: 

There are currently no treatments for Huntington's Disease (HD). KU researchers have developed a drug target for the treatment of Huntington's disease. Initial testing in cells demonstrates that this drug reduces cytotoxicity measured using an LDH assay. In neuronal cells, the drug has shown specificity toward the target, and reduced cell toxicity. In HD transgenic mice, this drug target can reduce motor dysfunction as measured on a rotorod test, and reduces weight loss. The data in both cells in culture and transgenic mice suggest that this approach will be a good target for drugs for the treatment of the disease.

Applications: 

Treatment for Huntington's Disease.

Licensing Associate: 
Aswini Betha, PhD · abetha@ku.edu · 913-588-5713
Subcategory(s): 
Keyword(s): 
Inventor(s): 
Nancy Muma
Patent(s): 
US 2010/0069304
Status: 
Patent-Pending